Address: 208 Bath Road, Slough, Berkshire, SL1 3WE,United Kingdom
Tel: +44 1 753 534 655
Web: http://www.ucb.com/
Company description
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009.
Products and services
Main therapeutic areas:
Immunology
Cimzia® (certolizumab pegol) – Crohn’s disease& Rheumatoid arthritis
Xyzal® (levocetirizine) – Allergies
Zyrtec® (cetirizine) – Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII) – Respiratory disease
Central Nervous System
Vimpat® (lacosamide) – Epilepsy
Keppra® (levetiracetam) – Epilepsy
Neupro® (rotigotine) – Parkinson’s disease & Restless Legs Syndrome
Nootropil® (piracetam) – Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII) – Attention Deficit Hyperactivity Disorder (ADHD)